Janssen's Ponvory (ponesimod) Receives the US FDA's Approval for the Treatment of Relapsing Multiple Sclerosis
Shots:
- The approval is based on the P-III head-to-head OPTIMUM trial involves assessing Ponvory (20 mg) vs Teriflunomide (14 mg) in adults with relapsing MS and follows >10 yrs of cumulative data demonstrating its efficacy and safety
- The results demonstrated superior efficacy in reducing annual relapses by 30.5%- no confirmed relapses (30.5% vs 61%)- reducing the number of new GdE T1 lesions and the number of new or enlarging T2 lesions by 59% and 56%- confirmed disability progression
- Ponvory (ponesimod) is a selective S1P1 modulator to treat adults with relapsing MS and is the 1st and only FDA-approved oral disease modifying therapy studied against an established oral comparator
Ref: PRNewswire | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com